Member Info for Hawker

@Mikemine - 100% agree with your comments. The fund managers and the house broker had the opportunity to create a positive feedback loop here, and instead they chose to create the opposite. They all get a big fat ‘F’ for their work here, shockingly poor quality investment management. No wonder their fund flows continue to vote with their feet.

Such a shame as the company are doing an increasingly material job of growing sales and executing on their objectives and milestones.

Thermo Fisher should soon be pushing PTRA, too.

Investors and brokers should be hanging their heads in shame on this round. Should have come at a significant premium to the last round, not to mention to the unsupported illiquid price on AIM.

I'm not so sure. I wouldn't be surprised to see Apollo return at some point, but yes, happy to pick up the divis in the meantime.

On one level, it's a pity the bid wasn't forthcoming, and that it failed to inspire others to get involved, but on the other, Bodycote remains a listed Plc, and that's good for the UK market as a whole. I had only started picking up shares around 650p, so I wasn't much invested when the news broke. I look forward to acquiring better value shares going forward and holding this for a good while.

There are many better growth days ahead for this business, especially in Aerospace and Defense.

Have added more today around 58p, looks right for the mid-term, if not before.

Sad to see, and just as the company is dailling up its growth...

I see that GLG Partners continues with their short position in Kainos. Looking at the history, they have been short since May 2023, and I would hazard a guess that their average price is around 950p a share.

Given the return to growth and a +21% YoY headcount increase, I think it would be fair to assume they have a strong H2.

Once this becomes clear we could well see the shares pop back above the £10 level, which may well be the catalyst that causes hedge funds like GLG to finally close their short. In the meantime, it has been a good source of relatively cheap financing for their long/short Equity Fund.

I am a happy holder (since 2019), with an average price of around 750p. think this goes back above £10 over the summer.

Well, let's see...

Looks like all the stop-losses have been triggered, oops!

Possibly led by a couple of hedge funds, I see the stock loan rate has moved up a couple of points this week.

I say let's focus on the fact that IQE now has over £80m in the bank and a strategic partner as an investor and customer.

I see this as very positive news.

Thermo Fisher can now crack on and start pushing the 'One Lambda Laboratories Pre-Transplant Risk Assessment (PTRA) assay' across their extensive US network.

This could well become a 'positive surprise' for VericiDX and their investors. Well, I'm not holding my breath, but the possibility is there.

Shares are not pricing any upside risk at this price, only doom and gloom, alas.

I see Deutsche Bank upgraded its forecasts and price target (860p to 920p) this morning, and Investec reiterated their Buy and PT at 1350p.

This is encouraging and bodes well for Kainos as it emerges as a leader (and winner) in the AI revolution.

After a pause, Kainos are now returning to material double-digit growth, and with a base of £431m, this could well become a £1bn+ revenue business over the next 5 years.

It's about time the UK had a sizeable leader in its own backyard, and a company that competes with the IBMs, MSFTs and PLTRs.

Keep up the good work, team Kainos, onwards and upwards!

That will do nicely, onwards and upwards for Kainos, who are clearly emerging as a material winner from AI.

On the point about possible flowback from the equity raise, I think it's worth adding that MACOM are taking £45m of the £81m as a strategic investment. We can assume this £45m is locked up for the foreseeable future. It may also be a way to dip their toe in for a possible acquisition later.

With this on the table, it makes even less sense to be short, so I would think the shorts will move to cover the rest of their short positions pronto.

Just thinking out loud...

Good to see the shorts reducing further this week.

My two cents are that IQE has raised just over £80m and has a new strategic investor on board in the industry they're selling into and scaling into.

Appreciate that it's early days, but they have de-risked the balance sheet and given themselves plenty of runway to build a stronger, more relevant, and more competitive business going forward.

Net net, there's now a really decent bull case here, and the bear case has clearly faded.

DYOR & GLA.

Suspect the hedge funds that have been short are driving the shares over the past few sessions, including today. I am happy to top-slice/sell a few into this move as the company is now on a valuation of around 5x revenues. The last time this was seen was in the euphoric days of 2017-18 when the shares were 150p+, and revs were over £150m. Happy days and GLA!

Hey SB,

That is a laudable goal, but their previous attempt to work with a distribution partner (EVERSANA, back in 2023, see link) appears to have generated little or no visible commercial traction. It would be helpful to understand why: is the issue product and market fit, or is it execution and personnel? And if it is either (or both), can it realistically be fixed before the bell tolls for the company?

https://renalytix.com/renalytix-selects-eversana-to-expand-commercialization-of-kidneyintelx-for-early-stage-kidney-disease-prognosis-detection-in-patients-with-type-2-diabetes/

I would like to think the company can still negotiate a genuinely successful distribution agreement, but for any further growth capital to be forthcoming, such a deal will almost certainly need hard minimum volume testing commitments and clear economic guarantees.

The Tempus agreement has (or had) this potential, much like RENX’s earlier partnerships with the VA, AstraZeneca, Atrium Health/Wake Forest and others, but none have yet translated into material revenues.

I live in hope (I genuinely do), but I fear this is shaping up as yet another cautionary tale from the AIM market, alas.

I suspect the recent damage to the share price is due to funds like Polar Capital trying to remove the last of their holding from their portfolio. It was Polar Capital who crashed the share price on the Tempus news.

RENX is in the last chance saloon, the raise at 9.5p will have been their last unless they can deliver something, anything, of material value from the Tempus "partnership", or any of their many other so-called "partnerships". Sad to see that this has been a serial disappointment since the lofty heights of 2021, such a shame. There is still time for James and the team to pull a rabbit out of the hat, but not much, alas.

Well spotted SB, I have been adding some today, too. I am keen to take advantage of the price drifting back to the recent placing price, which I think represents good opportunity value, given the growing momentum in repeat and new testing volumes. That seems to be the way of these things: a nice bounce on actual news, then drift back in the lull before the next news/reporting. According to the recent update in Feb, they're next due to report no later than May, so not long, and we could get some positive interim news before then, from Thermo, etc.

Net net, I'm happy to add shares at the 0.55/0.6p level.

DYOR & GLA.

Loving this move and almost forgot I had shares until the outsized increase this morning, happy days!

Shares are currently priced as if the company has no material revenue future. If the company demonstrates material growth in revs, then there's no reason the shares can't recover rapidly to where they were trading this time last year. It's a simple binary risk calculation, QED.

I bought more today at 0.59p, happy days.

DYOR & GLA.

Positive results from WorkDay (WDAY) in the US yesterday, underscoring that AI should give Kainos some tailwind.

Shorts may well be closing on the back of this, let's see.